Illumina Ventures

Profile

Illumina Ventures is a venture capital firm specializing in genomics and precision health investments, based in the United States. The firm was established as an independent entity and leverages its strategic relationship with Illumina Inc. to build promising healthcare companies. Illumina Ventures is known for its in-depth knowledge and expertise in the genomics field, as well as its commitment to transforming healthcare by investing in innovative science and technology. They are a small team of experienced professionals who operate as partners to entrepreneurs, providing not just capital but also mentorship and lab resources through their Illumina Ventures Labs.

The firm focuses on early-stage investments, supporting companies that work within life sciences tools, diagnostics, therapeutics, digital health, and sustainability sectors. They offer access to a fully equipped genomics lab, sequencing capabilities, and other resources to help startups succeed. Check sizes typically align with their seed-stage strategy, although precise ranges are not publicly stated. Illumina Ventures supports companies primarily in North America but is open to other regions showing promise in the genomics space.

Notable investments from Illumina Ventures' portfolio include Alamar Biosciences, which has launched a multiplexed blood-based immunoassay for Alzheimer’s research, and Iambic, which collaborates with Bayer to advance AI drug discovery. Additional portfolio companies include NuCicer, known for high-protein chickpeas, and others involved in groundbreaking health solutions.